U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H36F3N5O3
Molecular Weight 511.5802
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-04634817

SMILES

CO[C@@H]1COCC[C@@H]1N[C@@H]2CC[C@](C2)(C(C)C)C(=O)N3C[C@@H]4C[C@H]3CN4C5=NC=NC(=C5)C(F)(F)F

InChI

InChIKey=MCRWZBYTLVCCJJ-DKALBXGISA-N
InChI=1S/C25H36F3N5O3/c1-15(2)24(6-4-16(10-24)31-19-5-7-36-13-20(19)35-3)23(34)33-12-17-8-18(33)11-32(17)22-9-21(25(26,27)28)29-14-30-22/h9,14-20,31H,4-8,10-13H2,1-3H3/t16-,17+,18+,19+,20-,24+/m1/s1

HIDE SMILES / InChI

Description

PF-04634817 is a small molecule chemokine CCR2 and CCR5 receptor dual antagonist. Treatment with PF-04634817 was associated with a modest improvement in best-corrected visual acuity, which was inferior to intravitreal ranibizumab. Analysis of the primary endpoint, Urine Albumin-to-Creatinine Ratio, indicated a modest effect of PF-04634817 in reducing albuminuria in subjects with type 2 diabetes who received angiotensin receptor blocker therapy after 12 weeks of treatment. Despite the tolerable safety profile shown by PF-04634817, clinical development was discontinued in light of the modest efficacy observed.

Originator

Approval Year

Unknown
139594
PubMed

PubMed

TitleDatePubMed
A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema.
2018 May 1
Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy.
2018 Nov

Sample Use Guides

In Vivo Use Guide
200 mg once daily
Route of Administration: Oral
Name Type Language
PF-04634817
Common Name English
1,5-ANHYDRO-2,3-DIDEOXY-4-O-METHYL-3-(((1R,3S)-3-(1-METHYLETHYL)-3-(((1S,4S)-5-(6-(TRIFLUOROMETHYL)-4-PYRIMIDINYL)-2,5-DIAZABICYCLO(2.2.1)HEPT-2-YL)CARBONYL)CYCLOPENTYL)AMINO)-D-ERYTHRO-PENTITOL
Systematic Name English
D-ERYTHRO-PENTITOL, 1,5-ANHYDRO-2,3-DIDEOXY-4-O-METHYL-3-(((1R,3S)-3-(1-METHYLETHYL)-3-(((1S,4S)-5-(6-(TRIFLUOROMETHYL)-4-PYRIMIDINYL)-2,5-DIAZABICYCLO(2.2.1)HEPT-2-YL)CARBONYL)CYCLOPENTYL)AMINO)-
Systematic Name English
Code System Code Type Description
SMS_ID
300000041328
Created by admin on Sat Dec 16 11:35:41 GMT 2023 , Edited by admin on Sat Dec 16 11:35:41 GMT 2023
PRIMARY
DRUG BANK
DB14955
Created by admin on Sat Dec 16 11:35:41 GMT 2023 , Edited by admin on Sat Dec 16 11:35:41 GMT 2023
PRIMARY
FDA UNII
51M3FB9B9E
Created by admin on Sat Dec 16 11:35:41 GMT 2023 , Edited by admin on Sat Dec 16 11:35:41 GMT 2023
PRIMARY
PUBCHEM
46198579
Created by admin on Sat Dec 16 11:35:41 GMT 2023 , Edited by admin on Sat Dec 16 11:35:41 GMT 2023
PRIMARY
CAS
1228111-63-4
Created by admin on Sat Dec 16 11:35:41 GMT 2023 , Edited by admin on Sat Dec 16 11:35:41 GMT 2023
PRIMARY
ChEMBL
CHEMBL3545032
Created by admin on Sat Dec 16 11:35:41 GMT 2023 , Edited by admin on Sat Dec 16 11:35:41 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of PF-04634817
SALT/SOLVATE (PARENT)
Structure of PF-04634817 SUCCINATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966